Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 European Society of Cardiology Congress.

IF 5.7 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Current Atherosclerosis Reports Pub Date : 2024-12-02 DOI:10.1007/s11883-024-01253-z

Vashma Junaid, Abdul Mannan Khan Minhas, Maha Inam, Colin Hinkamp, Khawaja M Talha, Chelsea Meloche, Sana Sheikh, Adeel Khoja, Chayakrit Krittanawong, Elizabeth M Vaughan, Dinesh K Kalra, Leandro Slipczuk, Salim S Virani

{"title":"Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 European Society of Cardiology Congress.","authors":"Vashma Junaid, Abdul Mannan Khan Minhas, Maha Inam, Colin Hinkamp, Khawaja M Talha, Chelsea Meloche, Sana Sheikh, Adeel Khoja, Chayakrit Krittanawong, Elizabeth M Vaughan, Dinesh K Kalra, Leandro Slipczuk, Salim S Virani","doi":"10.1007/s11883-024-01253-z","DOIUrl":null,"url":null,"abstract":"Purpose of review: To summarize selected late-breaking science on cardiovascular disease (CVD) prevention presented at the 2024 European Society of Cardiology (ESC) Congress.Recent findings: Key studies from the 2024 ESC Congress highlight advances in (CVD) management. Apolipoprotein A-1 infusions reduced risk in acute myocardial infarction patients with high LDL cholesterol. Plozasiran cut triglycerides and apolipoprotein C-III levels, lowering pancreatitis risk. A 14-year study linked smoking among youth to cardiac abnormalities. Baseline hsCRP, LDL-C, and Lp(a) were strong predictors of 30-year outcomes in women. Alternative LDL-lowering strategies matched high-intensity statins in effectiveness of LDL-C lowering and reduced diabetes risk. Early combination lipid lowering therapy improved outcomes post-myocardial infarction. Nordic and Mediterranean diets were linked to lower atherosclerotic CVD risk. The findings from the 2024 ESC Congress highlight significant advancements in CVD prevention, including novel lipid-lowering therapies, biomarker-based risk prediction, and lifestyle interventions. These studies underscore the importance of early and personalized treatment strategies to mitigate long-term cardiovascular risk.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"14"},"PeriodicalIF":5.7000,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Atherosclerosis Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11883-024-01253-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: To summarize selected late-breaking science on cardiovascular disease (CVD) prevention presented at the 2024 European Society of Cardiology (ESC) Congress.

Recent findings: Key studies from the 2024 ESC Congress highlight advances in (CVD) management. Apolipoprotein A-1 infusions reduced risk in acute myocardial infarction patients with high LDL cholesterol. Plozasiran cut triglycerides and apolipoprotein C-III levels, lowering pancreatitis risk. A 14-year study linked smoking among youth to cardiac abnormalities. Baseline hsCRP, LDL-C, and Lp(a) were strong predictors of 30-year outcomes in women. Alternative LDL-lowering strategies matched high-intensity statins in effectiveness of LDL-C lowering and reduced diabetes risk. Early combination lipid lowering therapy improved outcomes post-myocardial infarction. Nordic and Mediterranean diets were linked to lower atherosclerotic CVD risk. The findings from the 2024 ESC Congress highlight significant advancements in CVD prevention, including novel lipid-lowering therapies, biomarker-based risk prediction, and lifestyle interventions. These studies underscore the importance of early and personalized treatment strategies to mitigate long-term cardiovascular risk.

查看原文本刊更多论文

在2024年欧洲心脏病学会大会上介绍的心血管疾病预防研究亮点。

综述的目的：总结2024年欧洲心脏病学会（ESC）大会上发表的关于心血管疾病（CVD）预防的最新科学成果。最新发现：2024年ESC大会的关键研究强调了心血管疾病管理的进展。载脂蛋白A-1输注可降低高LDL胆固醇急性心肌梗死患者的风险。plzasiran降低甘油三酯和载脂蛋白C-III水平，降低胰腺炎风险。一项长达14年的研究将青少年吸烟与心脏异常联系起来。基线hsCRP、LDL-C和Lp(a)是女性30年预后的有力预测因子。其他低密度脂蛋白降低策略与高强度他汀类药物在降低LDL-C和降低糖尿病风险方面的有效性相匹配。早期联合降脂治疗可改善心肌梗死后的预后。北欧和地中海饮食与较低的动脉粥样硬化性心血管疾病风险有关。2024年ESC大会的研究结果强调了心血管疾病预防方面的重大进展，包括新型降脂疗法、基于生物标志物的风险预测和生活方式干预。这些研究强调了早期和个性化治疗策略对于降低长期心血管风险的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Atherosclerosis Reports 医学-

CiteScore

9.00

自引率

3.40%

发文量

审稿时长

6-12 weeks

期刊介绍： The aim of this journal is to systematically provide expert views on current basic science and clinical advances in the field of atherosclerosis and highlight the most important developments likely to transform the field of cardiovascular prevention, diagnosis, and treatment. We accomplish this aim by appointing major authorities to serve as Section Editors who select leading experts from around the world to provide definitive reviews on key topics and papers published in the past year. We also provide supplementary reviews and commentaries from well-known figures in the field. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.